Summary
Chronic hepatitis B continues to pose a major global health challenge, affecting millions globally. ~5 million prevalent CHB cases across the 7MM in 2024.
No complete cure exists yet, but advances in antivirals and novel modalities are reshaping therapeutic outcomes and hope for a functional cure.
The potential drugs that can mark a significant change in the forecast period include GSK3228836 (GSK), tobevibart (VIR-3434) + elebsiran (VIR-2218) ± PEG-IFN-α (Vir Biotechnology), Imdusiran (Arbutus Biopharma), and others.
CHB market valued at ~USD 1.5 billion in 2024, with a projected 12.3% CAGR (2025–2034).
Chronic hepatitis B (CHB) remains one ...
